Zhengyu Zha
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Optimizing clinical strategies for nutritional and immune indices prediction of chronic lung diseases: a cross-sectional study from NHANES 2007-2012.
Journal: Therapeutic advances in respiratory disease
Published: March 15, 2026
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer.
Journal: Signal transduction and targeted therapy
Published: October 07, 2024
Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer.
Journal: Signal transduction and targeted therapy
Published: July 16, 2023
Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages.
Journal: Cell reports. Medicine
Published: September 30, 2022
Erratum to 'Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma' [J Hepatol 2021 (907-918)].
Journal: Journal of hepatology
Published: April 30, 2022
Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: April 07, 2020
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
Journal: The Journal of clinical investigation
Published: November 07, 2018
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.
Journal: American journal of cancer research
Published: July 30, 2018
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.
Journal: Cancer cell
Published: March 16, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026